Sacituzumab Govitecan-hziy (SG)

DRUG6 trials

Conditions

Advanced or Metastatic Non-Small-Cell Lung CancerCarcinoma Breast Stage IVCervical CancerEndometrial CancerEsophageal CancerGastric AdenocarcinomaGlioblastoma MultiformeHead and Neck Cancers- Squamous Cell

Phase 1

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

CompletedNCT01631552

Gilead SciencesCarcinoma Breast Stage IV, Cervical Cancer, Endometrial Cancer +13

Start: 2012-12-17End: 2020-08-13Updated: 2021-08-12

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

RecruitingNCT06926920

Gilead SciencesTriple Negative Breast Cancer

Start: 2025-04-30End: 2028-06-01Target: 100Updated: 2026-01-30

Phase 2

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Active, not recruitingNCT05186974

Gilead SciencesNon-small Cell Lung Cancer

Start: 2022-05-30End: 2026-09-01Updated: 2026-02-11

Study of Novel Treatment Combinations in Patients With Lung Cancer

RecruitingNCT05633667

Gilead SciencesAdvanced or Metastatic Non-Small-Cell Lung Cancer, Lung Cancer, Resectable Non-Small-Cell Lung Cancer

Start: 2023-03-16End: 2029-09-01Target: 270Updated: 2026-03-17

Phase 3

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT05089734

Gilead SciencesNon-Small Cell Lung Cancer

Start: 2021-11-17End: 2026-01-31Updated: 2025-05-23

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

RecruitingNCT05633654

Gilead SciencesTriple Negative Breast Cancer

Start: 2022-12-12End: 2031-08-01Target: 1514Updated: 2026-01-20

2025-10-30

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.

2025-10-30

Abstract A008: TIGIT, CD155 (PVR), and Trop-2 expression characterization across histology and PD-L1 subgroups in non−small cell lung cancer (NSCLC)

Molecular Cancer Therapeutics2025-10-22

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using <scp>HR</scp>+/<scp>HER2</scp>− Metastatic Breast Cancer Data From the Phase 3 <scp>TROPiCS</scp>‐02 Trial

Clinical and Translational Science2025-07-01

Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2025-05-282 citations

Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2025-05-28

Abstract LB399: Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer

Cancer Research2025-04-252 citations

Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01

Cancer Research2025-04-252 citations

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

UNC Libraries2024-10-09

Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors

International Journal of Clinical Oncology2024-09-209 citations

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Future Oncology2024-06-2614 citations

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.

2024-06-2110 citations

Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

Journal of Clinical Oncology2024-06-057 citations

Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.

Journal of Clinical Oncology2024-06-0116 citations

Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.

Journal of Clinical Oncology2024-06-016 citations

VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2024-06-012 citations

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.

2024-04-0517 citations

60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study

ESMO Open2024-03-012 citations

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.

Journal of Clinical Oncology2023-06-0114 citations

VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2023-06-012 citations

37 more papers not shown

Sacituzumab Govitecan-hziy (SG)

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers